d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats

Shimazaki, Toshiharu; Kaku, Ayaka; Chaki, Shigeyuki

doi:10.1007/s00213-010-1794-y

Cited by 79 publications

(50 citation statements)

References 44 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1A, 2A, and 3), indicating that MK-801 impaired short-term social memory, as we previously reported (16). The administration of the mGlu2/3-receptor agonist LY379268 and the mGlu2-receptor potentiator BINA significantly improved the social memory impairment elicited by MK-801 in rats {[F(2,32) = 5.51, P < 0.01] and [F(2,43) = 4.75, P < 0.05] (Figs.…”

Section: Effects Of the Mglu2/3-receptor Agonist And The Mglu2-receptsupporting

confidence: 83%

“…The social recognition test was performed as described previously (16). The behavior tests were performed in an open-topped box (28 × 47 × 30 cm, length × width × height) containing sawdust.…”

Section: Social Recognition Testmentioning

confidence: 99%

“…Therefore, the development of novel drugs that can improve social cognitive dysfunction in schizophrenia is desired. We previously demonstrated that social memory was impaired by a non-competitive NMDA-receptor antagonist, 11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine hydrogen maleate (MK-801), and that impaired social cognition was improved by treatment with the atypical antipsychotic clozapine, but not the typical antipsychotic haloperidol (16). Therefore, MK-801-induced social memory impairment may be useful as an animal model for evaluating the improvement of cognitive impairment, although social memory in rodents is a far simpler construct than in humans.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Stimulation of Metabotropic Glutamate (mGlu) 2 Receptor and Blockade of mGlu1 Receptor Improve Social Memory Impairment Elicited by MK-801 in Rats

et al. 2013

Self Cite

View full text Add to dashboard Cite

Abstract. Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. Both the stimulation of the metabotropic glutamate (mGlu) 2/3 receptor and the blockade of the mGlu1 receptor have been shown to be effective in a number of animal models of schizophrenia. However, the efficacy for social cognition, which is poorly managed by current medication, has not been fully addressed. The present study evaluated the effects of an mGlu2/3-receptor agonist and an mGlu1-receptor antagonist on social memory impairment in rats. Pretreatment with an mGlu2/3-receptor agonist, (−)-2-oxa-4-aminobicyclo[3. propanoic acid (LY341495). These findings indicate that both the stimulation of the mGlu2 receptor and the inhibition of an mGlu1 receptor improve social memory impairment elicited by MK-801, and both manipulations could be effective approaches for the treatment of certain cognitive dysfunctions observed in schizophrenic patients.

show abstract

Section: Effects Of the Mglu2/3-receptor Agonist And The Mglu2-receptsupporting

confidence: 83%

Section: Social Recognition Testmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stimulation of Metabotropic Glutamate (mGlu) 2 Receptor and Blockade of mGlu1 Receptor Improve Social Memory Impairment Elicited by MK-801 in Rats

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…The social recognition test was performed as described previously (14). The behavior tests were performed in an open-topped box (47 cm width Â 28 cm length Â 30 cm height) containing sawdust.…”

Section: Social Recognition Testmentioning

confidence: 99%

Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor

Hikichi

Hiyoshi

Marumo

et al. 2015

Journal of Pharmacological Sciences

Self Cite

View full text Add to dashboard Cite

Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia. In this study, we investigated the antipsychotic profiles of (2S)-5-methyl-2-{[4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]oxazole-6-carboxamide (TASP0443294), a newly synthesized positive allosteric modulator of the mGlu2 receptor. TASP0443294 potentiated the response of human mGlu2 and rat mGlu2 receptors to glutamate with EC50 values of 277 and 149 nM, respectively, without affecting the glutamate response of human mGlu3 receptor. TASP0443294 was distributed in the brain and cerebrospinal fluid after peroral administration in rats. The peroral administration of TASP0443294 inhibited methamphetamine-induced hyperlocomotion in rats, which was attenuated by an mGlu2/3 receptor antagonist, and improved social memory impairment induced by 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801) in rats. Furthermore, TASP0443294 reduced the ketamine-induced basal gamma hyperactivity in the prefrontal cortex and suppressed rapid eye movement (REM) sleep in rats. These findings indicate that TASP0443294 is an mGlu2 receptor positive allosteric modulator with antipsychotic activity, and that the suppression of aberrant gamma oscillations and REM sleep could be considered as neurophysiological biomarkers for TASP0443294.

show abstract

“…Exogenous administration of D-serine leads to improvements in specific features of spatial memory in the Morris water maze, such as reversal learning (Duffy et al 2008), probe test retrieval (Zhang et al 2008), and day-to-day savings in the delayed-match-to-place version of the task (Stouffer et al 2004). In addition, D-serine administration improves social memory in rats (Shimazaki et al 2010). However, most of the above cited studies used doses of 600-1,300 mg/kg (with the exception of that by Stouffer et al 2004, which used 100 mg/kg), far above the range shown to be effective in clinical trials with schizophrenia patients (30-120 mg/kg).…”

Section: Introductionmentioning

confidence: 96%